The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus

Abstract

It is known that COVID-19 patients with concomitant type 2 diabetes mellitus and severe dyslexic disorders are characterized by a more severe course of combined pathology. In this regard, the choice of hypoglycemic therapy for effective management of glycemia is important. The review examines publications shedding light on the therapeutic potential of taking gliclazide MV in patients with a combination of mild COVID-19 and diabetes mellitus.